Brandt T, Frangiosa T, Biggar V, Taylor A, Valentine J, Keller B, Price M, DeMuro C, Abler V. Symptoms and treatment needs of people with dementia-related psychosis: a mixed-methods study of the patient experience. Clin Gerontol. 2021 Aug 9;45(3):681-95. doi: 10.1080/07317115.2021.1957050
Clark M, Berry P, Martin S, Harris N, Sprecher D, Olitsky S, Hoag JB. Nosebleeds in hereditary hemorrhagic telangiectasia: development of a patient-completed daily eDiary. Laryngoscope Investig Otolaryngol. 2018 Nov 14;3(6):439-45. doi: 10.1002/lio2.211
Yosipovitch G, Reaney M, Eckert L, Nelson L, Clark M, Abbe A, Ardeleanu M, Radin A, Gadkari A. Validation of the peak pruritus numerical rating scale: results from clinical studies of dupilumab in adults with moderate-to-severe atopic dermatitis. Poster presented at the Australasian College of Dermatologists 50th Annual Scientific Meeting; May 2017. Sydney, Australia. [abstract] Australas J Dermatol. 2017 May; 58(S1):106-7. Previously presented at the 2017 American Academy of Dermatology Annual Meeting. doi: 10.1111/ajd.21_12652
Spelman LJ, Lebwohl M, Mordin M, Mallya UG, Gnanasakthy A, Fox T. Secukinumab treatment provides fast relief from patient-reported psoriasis burden. Poster presented at the 48th Australasian College of Dermatologists Annual Scientific Meeting; May 2015. Adelaide, Australia. [abstract] Australas J Dermatol. 2015 May; 56(Suppl 2):73.
Foley P, Sherif B, Mallya UG, Fox T, Gottlieb AB. Secukinumab treatment sustains patient-reported outcome benefits through 1 year. Poster presented at the 48th Australasian College of Dermatologists Annual Scientific Meeting; May 2015. Adelaide, Australia. [abstract] Australas J Dermatol. 2015 May; 56(Suppl 2):56.
Sinclair R, McLeod L, Mallya UG, Fox T, Strober B. Psoriasis patients with PASI90 response achieve greater health-related quality of life improvements than those with PASI75 response. Poster presented at the 48th Australasian College of Dermatologists Annual Scientific Meeting; May 2015. Adelaide, Australia. [abstract] Australas J Dermatol. 2015 May; 56(S2):68.
Novick D, Montgomery W, Brnabic A, Aguado J, Kadziola Z, Peng X, Brugnoli R, Haro JM. Prognostic implications of somatic symptoms in patients with depression. Results from a three-month, prospective, observational study from Asia. Poster presented at the 28th CINP World Congress of Neuropsychopharmacology; June 3, 2012. Stockholm, Sweden. [abstract] Int J Neuropsychopharmacol. 2012 Jun; 15(1):191. doi: 10.1017/S1461145712000508
Eap CB, Vandenberghe F, Choong E, Saigi-Morgui N, Ambresin AE, von Gunten A, Conus P. Clinical and pharmacogenetic study on psychotropic drug induced weight gain and other metabolic complications in a Swiss psychiatric population. Poster presented at the 2012 World Congress of the International College of Neuropsychopharmacology; June 2012. Stockholm, Sweden. [abstract] Int J Neuropsychopharmacol. 2012 Jun 1; 15(Suppl 1):101. doi: 10.1017/S1461145712000508
Williams VS, Feltner D, Hill C, Morlock R. Evaluation of a global anxiety – Visual analog scale (ga-vas) in a clinical trial comparing lorazepam and paroxetine in patients with gad. Poster presented at the CINP 25th Biennial Congress; July 2006. [abstract] Int J Neuropsychopharmacol. 2006 Jul; 9(Suppl 1):S118.
Longo C, Raskin J, Gilsenan AW, Corey-Lisle P, Hopkins JS, Sherrill BH. Prevalence of treatment-resistant depression in Saskatchewan - limitations of a claims-based analysis. Int J Neuropsychopharmacol. 2002 Jun 1;5(Suppl 1):S141. doi: 10.1017/S1461145702003176